While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Oncogenic proteins like BCR-ABL can alter cell signaling pathways through protein-protein interactions, promoting malignancy.
• BCR-ABL signaling is crucial for uncontrolled cellular proliferation in leukemic cells, integrating various signals.
• Resistance to apoptosis and the role of microRNAs (miRNAs) are critical factors in BCR-ABL-positive leukemias.

Purpose of the Study:

• To review recent advancements in understanding resistance to TRAIL-mediated apoptosis in BCR-ABL-positive leukemias.
• To explore the dual roles of miRNAs in BCR-ABL-mediated leukemogenesis.
• To highlight emerging research on BCR-ABL's nuclear functions and their implications in apoptosis.

Main Methods:

• Literature review of recent studies on BCR-ABL signaling, apoptosis, and miRNAs in leukemia.
• Analysis of molecular mechanisms underlying resistance to TRAIL-mediated apoptosis.
• Investigation of the interplay between BCR-ABL, oncomirs, and apoptosis-regulating genes.

Main Results:

• BCR-ABL promotes carcinogenesis via antiapoptotic proteins and oncomirs that target death receptors and pro-apoptotic genes.
• Specific oncomirs suppress SMAD, inversely correlating with TRAIL expression, a key area of research.
• Emerging evidence suggests novel nuclear roles for BCR-ABL influencing apoptosis.

Conclusions:

• Genetic heterogeneity in leukemias presents significant therapeutic challenges.
• Targeting cancer-promoting molecular machinery requires further validation for clinical application.
• Personalized medicine, driven by advanced technologies, holds promise for improving leukemia treatment efficacy and patient survival.